Allergic conjunctivitis is fundamentally a mast cell disease. The conjunctiva — the thin, vascularised mucous membrane covering the white of the eye and lining the inner eyelids — contains one of the highest densities of mast cells of any mucous membrane in the body. A healthy human conjunctiva hosts approximately 5,000–6,000 mast cells per mm². In patients with chronic allergic eye disease, this density is 2–3× higher — a sensitised eye literally has more inflammatory cells lying in wait.

Understanding this pathway explains every clinical decision in allergic eye disease. Antihistamines block histamine at H1 receptors — providing rapid relief of acute itch and redness. Mast cell stabilisers (sodium cromoglycate, nedocromil, lodoxamide) prevent degranulation from occurring — but require consistent use before allergen exposure to be effective. Dual-action agents (olopatadine, ketotifen, bepotastine) do both simultaneously, making them the preferred first-line agents. Corticosteroids suppress the entire inflammatory cascade downstream of mast cell activation — which is why they work so dramatically, and why the risks of their chronic use must be taken equally seriously.

India's allergic eye disease burden has three drivers that have no equivalent in temperate climates.

Climate: Hot, dry, dusty environments dramatically increase airborne particulate exposure. India's semi-arid zones — spanning Rajasthan, Gujarat, Maharashtra, Telangana, and Karnataka — create ideal conditions for both dust mite proliferation in humid conditions and pollen dispersal in dry seasons. Rapid urban development has introduced novel sensitisers: vehicle exhaust particulates, industrial pollutants, and construction dust all act as non-allergenic adjuvants that enhance IgE sensitisation to co-present allergens.

Atopic background: India's large atopic population — with high rates of atopic dermatitis, allergic rhinitis, and asthma — provides the sensitised immune background on which VKC disproportionately occurs. The "atopic march" (progression from eczema to rhinitis to asthma to ocular allergy) is well characterised globally; in India's hot-climate zones, VKC occurs within this march at much higher frequency than in European populations.

Awareness gap: Parents of children with VKC routinely present to pharmacists, receive topical antibiotic-steroid combinations (the ubiquitous "combination drop" containing tobramycin + dexamethasone), and use them continuously for months without any IOP monitoring. The result is a steady stream of children arriving at tertiary eye hospitals with steroid-induced glaucoma, posterior subcapsular cataracts, and corneal shield ulcers — all from VKC that was treated incorrectly at the primary level.

The International Ocular Allergy Working Group classifies allergic conjunctivitis into five distinct clinical entities. The distinction matters enormously — SAC and PAC are essentially self-limiting nuisances; VKC and AKC can permanently blind. Treating them all as "eye allergy" and prescribing the same drops misses the point entirely.

VKC deserves its own section because it is where India's burden diverges most sharply from the global picture. It is categorically different from seasonal allergic conjunctivitis in mechanism, severity, management, and prognosis — and it is being undertreated at epidemic scale across India's tier-2 and tier-3 cities.

VKC is driven by a dual mechanism: IgE-mediated mast cell degranulation plus Th2 lymphocyte-driven eosinophilic inflammation. This combination produces the characteristic giant papillae (formed by subepithelial eosinophil accumulation and fibrosis), and the intense cytokine milieu that damages the corneal epithelium.

• Shield ulcer — the most dreaded complication. Toxic mucous plaque deposits on the superior cornea under the mechanical abrasion of giant papillae, creating a non-healing oval corneal ulcer. The plaque prevents re-epithelialisation. Treatment requires mechanical débridement, bandage contact lens, and aggressive anti-inflammatory therapy. Failure → permanent corneal scar → amblyopia in children.
• Trantas dots — whitish dots of eosinophil clusters at the limbus (cornea-sclera junction). Pathognomonic of active VKC. Named after the Greek ophthalmologist Adaeos Trantas who described them in 1910.
• Pseudogerontoxon — a white arc at the superior limbus resembling arcus senilis, representing subepithelial eosinophil deposition. Its presence in a child should always prompt full VKC assessment.
• Keratoconus association — VKC is the strongest modifiable risk factor for keratoconus in children. Eye rubbing from intense pruritus causes progressive corneal ectasia. Stopping eye rubbing is a therapeutic intervention in VKC — parents must be explicitly counselled about this.

The clinical diagnosis of allergic conjunctivitis is primarily symptomatic — but the symptom must be correctly identified. The single most reliable distinguishing feature between allergic conjunctivitis and dry eye disease is the quality of the dominant ocular symptom.

• Itching (pruritus) — the cardinal and almost pathognomonic symptom of allergic conjunctivitis. If a patient with a red, watery eye denies significant itching, allergic conjunctivitis is less likely.
• Burning / stinging / grittiness — the dominant symptom of dry eye disease (see our Dry Eye guide).
• Photophobia without corneal staining — suggests uveitis (see our Uveitis guide).
• Unilateral red eye with corneal white spot — keratitis until proven otherwise (see our Corneal Ulcer guide).

The slit lamp examination in allergic conjunctivitis focuses on: papillae vs follicles (papillae = allergic; follicles = viral/chlamydial), location (upper tarsal = VKC; lower tarsal = SAC/PAC), limbal findings (Trantas dots = VKC), and corneal involvement (shield ulcer, punctate epithelial erosions). Upper lid eversion — essential but frequently omitted in busy outpatient settings — is mandatory in any suspected VKC case. Papillae >1mm on the upper tarsal conjunctiva are diagnostic of VKC.

Fluorescein staining differentiates corneal involvement: allergic conjunctivitis without corneal disease shows no staining; shield ulcers stain intensely. Using FLUROSCÉNE fluorescein strips at the slit lamp provides rapid, clean staining for epithelial defect assessment — the same technique used in corneal ulcer diagnosis and TBUT testing in dry eye.

• Fluorescein — stains areas where the epithelium is absent (ulcers, erosions). In VKC shield ulcer: bright focal central staining. In dry eye: punctate diffuse staining. In simple allergy without corneal disease: no staining.
• Rose Bengal / Lissamine Green — stains devitalised epithelial cells. More sensitive for detecting epithelial stress in chronic allergic eye disease before frank ulceration occurs. Also stains the "map" of goblet cell loss in chronic inflammation.

• Skin prick test (SPT) — gold standard for identifying specific IgE sensitisation. 20–30 common allergens tested simultaneously. Positive wheal >3mm after 15 minutes. Required before considering allergen-specific immunotherapy (AIT).
• Serum specific IgE (RAST/ImmunoCAP) — alternative where SPT is contraindicated (severe eczema, dermographism, beta-blocker use). More expensive than SPT; similar sensitivity.
• Conjunctival provocation test (CPT) — controlled application of dilute allergen directly to the conjunctiva; confirms IgE-mediated reaction locally. Mainly a research tool.
• Tear cytology — eosinophils in tear smear or conjunctival scraping are highly specific for allergic conjunctivitis. Eosinophil presence distinguishes allergic from viral/bacterial conjunctivitis in diagnostically ambiguous cases.

• Cold compress: Vasoconstriction reduces hyperaemia and oedema. Chilled (not frozen) cloth or eye mask applied for 10 minutes provides immediate relief. Safe, free, underused. Particularly effective during acute episodes in children.
• Allergen avoidance: Dust mite — mattress encasings, hot wash bedding, reduce carpets; Pollen — wrap-around glasses outdoors, close windows, shower after outdoor activity; Cockroach — professional pest control, sealed food storage.
• Preservative-free artificial tears: Dilute and flush allergens from the ocular surface. Use refrigerated — the cold provides additional relief. Preservative-free essential for patients using drops >4× daily. Also reduces the surface inflammation from allergen-induced goblet cell stress (connects to dry eye overlap — see our Dry Eye guide).

Olopatadine 0.1%/0.2%, ketotifen 0.025%, bepotastine 1.5%, cetirizine 0.24% — these dual-mechanism agents block H1 receptors (immediate histamine effect) and stabilise mast cells (reducing preformed and newly synthesised mediator release). They are the most evidence-based, most broadly applicable first-line agents in allergic conjunctivitis. Twice-daily dosing; works within minutes of instillation; minimal systemic absorption. Available in India generically and as branded products.

Monotherapy mast cell stabilisers (sodium cromoglycate 2–4%, nedocromil, lodoxamide) require 2–4 weeks of consistent use to reach full effect and must be started before allergen season to be effective. They are no longer first-line for established allergy but remain useful for VKC maintenance.

Ketorolac 0.4–0.5%, diclofenac 0.1% — inhibit prostaglandin synthesis via COX-1/COX-2 inhibition. Reduce ocular discomfort and pruritus as adjunct to antihistamine therapy. Not first-line monotherapy but useful in SAC/PAC not fully controlled by antihistamines. Side effects: burning on instillation, rare corneal melting with prolonged use.

The most effective anti-inflammatory agents available for ocular allergy. Prednisolone acetate 1%, fluorometholone 0.1%, dexamethasone 0.1%, and — most importantly — loteprednol etabonate 0.5%. Loteprednol is a "soft steroid" — metabolised to inactive metabolites after receptor binding, dramatically reducing IOP-raising and cataractogenic risk compared to prednisolone and dexamethasone. It should be the preferred steroid for allergic eye disease management wherever available.

Steroids must always be prescribed by an ophthalmologist with IOP monitoring at every follow-up. Duration should be as short as possible (typically 2–4 weeks for acute exacerbations; longer courses under close surveillance in VKC). The steroid risk section below covers this in full.

Topical cyclosporine inhibits T-cell activation and cytokine production (primarily IL-2) — targeting the lymphocyte-mediated component of VKC/AKC rather than the mast cell IgE pathway. It takes 4–8 weeks to reach full effect but enables steroid tapering in patients who would otherwise require chronic steroid use. Commercially available as Restasis (0.05%) in India; compounded 1–2% for severe VKC in some centres. Side effects: burning on instillation, improved over time. Now considered standard of care for moderate-severe VKC requiring long-term management.

For refractory VKC with giant papillae not responding to topical therapy, a sub-tarsal injection of triamcinolone acetonide (40 mg/mL, 0.5–1 mL) directly under the upper tarsal conjunctiva can induce rapid, sustained papillae regression. Reserved for severe cases in ophthalmologist hands; highly effective when indicated. IOP monitoring mandatory afterward — supratarsal steroids carry equivalent or higher systemic absorption than topical drops.

Subcutaneous immunotherapy (SCIT) or sublingual immunotherapy (SLIT) with gradually increasing doses of the specific allergen induces immune tolerance — converting the pathological Th2 response to a regulatory T-cell response. It is the only treatment that modifies the underlying allergic disease rather than suppressing symptoms. Effective primarily for single or limited sensitisations (house dust mite, single pollen). Duration: 3–5 years of weekly/monthly injections or daily sublingual tablets. Evidence in ocular allergy: strong for rhinoconjunctivitis; growing evidence for isolated ocular allergy.

The single most dangerous practice in the management of allergic eye disease in India is the indiscriminate dispensing — by pharmacists, general practitioners, and sometimes ophthalmologists — of topical steroid-antibiotic combination drops (tobramycin + dexamethasone is the most common offender) for itchy red eyes.

These combinations work rapidly and dramatically. The dexamethasone suppresses inflammation; the tobramycin provides antibiotic cover that is rarely needed. The patient feels better within 24 hours. They return for more when symptoms recur. Months pass. Then the complications arrive.

• Dry Eye Disease (overlap syndrome): 40–50% of patients with allergic conjunctivitis also have dry eye disease. Allergen-induced inflammation disrupts goblet cells (reducing mucin secretion) and damages meibomian glands (reducing lipid layer), directly destabilising the tear film. Treating allergic conjunctivitis without addressing concurrent DED leaves patients symptomatic. See our comprehensive Dry Eye Disease guide for the full diagnostic framework.
• Keratoconus: VKC is the strongest modifiable paediatric risk factor for keratoconus. Eye rubbing — driven by VKC itching — applies chronic shear stress to the corneal stroma, progressively thinning and steepening it. Eliminating eye rubbing (through itch control and behaviour modification) is literally cornea-preserving in VKC.
• Corneal ulcer susceptibility: Chronic allergic ocular surface inflammation reduces goblet cell density and impairs epithelial barrier function, increasing susceptibility to infectious keratitis. Combined steroid use further compounds this. See our Corneal Ulcer guide.
• Glaucoma (steroid-induced): As above — steroid use for allergic eye disease is one of the most common routes to secondary glaucoma in India. Full context in our Glaucoma guide.